Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will deliver two poster presentations at the 20th PEGS Boston Summit, the Essential Protein and Antibody Engineering Summit, being held May 13-17, 2024 in Boston, MA and virtually.
2024年5月8日,波士顿(GLOBE NEWSWIRE)- Cue生物制品公司(纳斯达克:CUE)是一家临床阶段的生物医药公司,开发一种新型疗法生物制品,选择性调节特异性疾病T细胞,今天宣布将于2024年5月13日至17日在波士顿和虚拟会议上举行的第20届PEGS波士顿峰会(必备的蛋白质和抗体工程峰会)上提供两个海报展示。
Presentation Details
报告详情
Date and Time: Monday, May 13 from 7:00 a.m. – 4:30 p.m. and Tuesday, May 14 from 9:00 a.m. – 12:00 p.m. EDT
Session: Poster Session A
Poster number: A028
Title: Immuno-STATs for Targeted Depletion of B Cells in Autoimmune Diseases
Presenter: Nitin Kumar, Scientist, Biologics Discovery and Innovation, Cue Biopharma
日期和时间:东部时间5月13日星期一早上7:00到下午4:30,星期二5月14日上午9:00到中午12:00
会议:海报展示会场A
海报编号:A028
标题:针对自身免疫性疾病的B细胞靶向清除的免疫STATs
演讲者:Cue生物制品公司生物制品发现和创新科学家Nitin Kumar
Dr. Kumar will discuss Cue Biopharma's newly deployed CUE-500 series of bispecific Immuno-STAT biologics, designed to redirect and activate cytotoxic anti-viral memory T cells to deplete pathogenic B cells, which is a therapeutically relevant mechanism for the treatment of several autoimmune diseases.
Kumar博士将讨论Cue生物制品公司新推出的CUE-500系列双特异性免疫STAT生物制品,旨在重定向和激活细胞毒性抗病毒记忆T细胞,以清除病原性B细胞,这是治疗几种自身免疫性疾病的一种治疗相关机制。
Date and Time: Tuesday, May 14 from 2:00 p.m. – 4:00 p.m. and Wednesday, May 15 from 9:00 a.m. – 7:30 p.m. EDT
Session: Poster Session B
Poster number: B023
Title: Immuno-STATs (ISTs): A Novel and Unique T-Cell Engager Platform for the Treatment of Immuno-Oncology and Autoimmune Diseases
Presenter: Ahmet Vakkasoglu, Associate Director, Biologics Discovery and Innovation, Cue Biopharma
日期和时间:东部时间5月14日星期二下午2:00到4:00,星期三5月15日上午9:00到下午7:30
会议:海报展示会场B
海报编号:B023
标题:免疫STAT(ISTs):治疗免疫肿瘤学和自身免疫性疾病的新型独特T细胞结合剂平台
演讲者:Cue生物制品公司生物制品发现和创新的副总裁Ahmet Vakkasoglu
Dr. Vakkasoglu will present an overview of Cue Biopharma's Immuno-STAT platform and biologics. This will include a discussion of our lead oncology assets, which have demonstrated clinical anti-tumor activity, as well as an overview of our next generation platforms and molecules for the treatment of cancer, autoimmune and inflammatory diseases.
Vakkasoglu博士将介绍Cue生物制品公司的免疫STAT平台和生物制品,包括我们的抗肿瘤主要资产,已经展示了临床抗肿瘤活性,以及我们下一代的平台和分子的概述,用于治疗癌症、自身免疫性和炎症性疾病。
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
关于cue biopharma
cue biopharma是一家临床阶段生物制品公司,正在开发一种新型的注射生物制品类别,以有选择性地在患者体内直接接触和调节疾病特异性T细胞。该公司的专有平台Immuno-STAT(选择性靶向和改变T细胞)和生物制品旨在通过选择性调节疾病特异性T细胞来利用体内免疫系统的治愈潜力,而不会产生广泛的系统免疫调节不良反应。
总部位于马萨诸塞州波士顿,我们由一支专业的管理团队和独立的董事会领导,他们拥有深厚的免疫学和免疫肿瘤学以及蛋白质生物制品设计和临床开发方面的专业知识。
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
欲知更多信息,请访问 X,并关注我们的 X 和 LinkedIn。
For more information please visit and follow us on X and LinkedIn.
Marie Campinell 高级总监,企业传讯 Cue Biopharma, Inc.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
投资者联系方式
Marie Campinell
高级董事,企业通信
cue biopharma,全球货币
mcampinell@cuebiopharma.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
媒体联系人
Jonathan Pappas
通信-半导体
jpappas@lifescicomms.com